All Pharmaceuticals articles – Page 6
-
ArticleMylan finalizes $30M EpiPen settlement with SEC
Mylan has finalized a previously disclosed $30 million settlement with the SEC for alleged accounting and disclosure failures surrounding its popular EpiPen.
-
ArticleMallinckrodt to pay $15.4M over kickback allegations
Pharmaceutical company Mallinckrodt is set to pay $15.4 million to the Justice Department to resolve allegations of illegal kickbacks to doctors in the form of lavish dinners and entertainment.
-
Article
Kadmon appoints general counsel, chief compliance officer
Kadmon Holdings announced the appointment of Gregory Moss as executive vice president, general counsel, and corporate secretary. Moss will also serve as chief compliance officer.
-
Article
Jaguar Health appoints chief accounting officer
Jaguar Health announced the promotion of Carol Lizak to chief accounting officer. Lizak formerly served as Jaguar’s vice president of finance and corporate controller.
-
ArticleTherapeuticsMD to pay $200K for Reg FD violations
Pharmaceutical company TherapeuticsMD agreed to pay a $200,000 penalty to resolve charges brought by the SEC for Reg FD violations. The case imparts some compliance lessons.
-
ArticleAspen to pay $9.7M to settle U.K. competition concerns
Aspen Pharmacare has offered to pay the U.K.’s National Health Service £8 million (U.S. $9.7 million) following suspicions that the company paid rival firms to delay marketing a vital medicine to retain market dominance.
-
ArticleChief compliance officer liability and the opioid epidemic
In a period of three months, two chief compliance officers have been charged for their individual roles in the opioid epidemic—a clear indication the Department of Justice continues to expand the scope of prosecutions to those who fail in their compliance responsibilities.
-
ArticleBlockchain: The new frontier for supply chain risk management
A new pilot project currently being explored by the U.S. Food and Drug Administration has enlisted IBM, KPMG, Merck, and Walmart to help determine how to incorporate blockchain into pharmaceutical supply chains.
-
ArticleNovartis sets aside $700M in kickback case
Swiss pharmaceutical drug maker Novartis announced it has set aside $700 million for a potential settlement in a long-running lawsuit over allegations that the company paid hundreds of millions of dollars in kickbacks to doctors to induce them into prescribing drugs to patients to boost their sales.
-
ArticleReckitt Benckiser’s record $1.4B opioid settlement a warning for drug companies
Reckitt Benckiser Group will pay $1.4 billion to resolve a long-running federal investigation concerning the sales and marketing of the opioid addiction treatment drug Suboxone.
-
ArticleFlorida man sentenced for role in collapse of Puerto Rico bank
The CEO of a now-bankrupt pharmaceutical company was sentenced to 30 years in prison for his role in a $100 million plot that triggered Westernbank of Puerto Rico’s collapse.
-
Article
Intra-Cellular Therapies appoints chief compliance officer
Intra-Cellular Therapies, a biopharmaceutical company, has appointed Karen Sheehy as chief compliance officer.
-
Article
Menlo Therapeutics names chief compliance officer
Biopharmaceutical company Menlo Therapeutics has appointed Ronald Krasnow as general counsel and chief compliance officer.
-
ArticleInsys files for bankruptcy after $225M settlement
Opioid maker Insys Therapeutics has filed for bankruptcy after agreeing to a $225 million global resolution to settle investigations concerning deceptive marketing and distribution of the drug Subsys.
-
ArticleHeritage Pharmaceuticals admits to price fixing, antitrust violations
Heritage Pharmaceuticals, a generic pharmaceutical company headquartered in New Jersey, was charged with conspiring with competitors to fix prices, rig bids, and allocate customers.
-
ArticleNew rule: Companies must reveal drug costs in TV ads
Under a new rule enacted by the Department of Health and Human Services, pharmaceutical companies will soon be required to disclose in television commercials the price of their prescription drugs that cost more than $35 per month.
-
ArticleJim Massey: The life coach
As a sustainability leader and a fighter for equal access to healthcare, Jim Massey doesn’t just talk the talk; he walks the walk. “It’s about doing the right thing all the time,” he says.
-
ArticleAstellas, Amgen to pay $124.75M for False Claims Act violations
Pharmaceutical companies Astellas and Amgen will pay a total of $124.75 million to resolve allegations that they violated the False Claims Act by illegally paying the Medicare co-pays for their own high-priced drugs.
-
Article
Walgreens Boots Alliance names chief accounting officer
Walgreens Boots Alliance, a retail pharmacy company, has named Heather Dixon as its new global controller and chief accounting officer, effective March 18.
-
ArticleIndrani Franchini: The champion of culture
For almost 20 years, Indrani Franchini has made a career out of getting to know the industry she is in, creating business relationships that build value and driving cultural change.